Literature DB >> 17694676

HIV and malaria.

Maria Dolores Herrero1, Pablo Rivas, Norma I Rallón, Germán Ramírez-Olivencia, Sabino Puente.   

Abstract

Malaria and HIV infection are both prevalent in the areas of the world where these diseases have the largest burden. Both diseases interact with one another and this interaction is especially important in areas with non-continuous malaria transmission, in pregnant women, and in patients with more severe immunodeficiency. Malaria has been implicated in transitory higher viral load and in low CD4 counts, so it could have an influence on higher transmission rates of HIV and perhaps in the course of HIV infection. Infection with HIV has been shown to cause more clinical malaria and higher parasitemia in patients living in perennial transmission areas, and higher rates of severe malaria episodes and mortality in areas where malaria is transmitted with seasonal frequency. The HIV-infected patients have also higher rates of malaria treatment failures. Co-trimoxazole prophylaxis has been shown to be effective in the prevention of some opportunistic infections in HIV-infected patients, but also in prevention of malaria episodes. Antiretroviral protease inhibitors demonstrate antimalarial effects that could have important clinical and therapeutic implications. For all of these reasons, HIV and malaria should be considered together as part of healthcare programs for both diseases in countries where their co-presence favors an interaction with important clinical consequences.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17694676

Source DB:  PubMed          Journal:  AIDS Rev        ISSN: 1139-6121            Impact factor:   2.500


  10 in total

1.  Evaluation of the effect of pyrimethamine, an anti-malarial drug, on HIV-1 replication.

Authors:  Raphael M Oguariri; Joseph W Adelsberger; Michael W Baseler; Tomozumi Imamichi
Journal:  Virus Res       Date:  2010-08-26       Impact factor: 3.303

2.  Surviving Sepsis in High HIV Prevalence Settings.

Authors:  Ben Andrews
Journal:  Med J Zambia       Date:  2010

3.  No evidence of association between HIV-1 and malaria in populations with low HIV-1 prevalence.

Authors:  Diego F Cuadros; Adam J Branscum; Gisela García-Ramos
Journal:  PLoS One       Date:  2011-08-12       Impact factor: 3.240

4.  The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatment.

Authors:  Betty A Maganda; Eliford Ngaimisi; Appolinary A R Kamuhabwa; Eleni Aklillu; Omary M S Minzi
Journal:  Malar J       Date:  2015-04-25       Impact factor: 2.979

5.  Frequency and distribution patterns of opportunistic infections associated with HIV/AIDS in Uganda.

Authors:  John Rubaihayo; Nazarius M Tumwesigye; Joseph Konde-Lule; Henry Wamani; Edith Nakku-Joloba; Fredrick Makumbi
Journal:  BMC Res Notes       Date:  2016-12-07

6.  HIV infection drives IgM and IgG3 subclass bias in Plasmodium falciparum-specific and total immunoglobulin concentration in Western Kenya.

Authors:  Eliud O Odhiambo; Dibyadyuti Datta; Bernard Guyah; George Ayodo; Bartholomew N Ondigo; Benard O Abong'o; Chandy C John; Anne E P Frosch
Journal:  Malar J       Date:  2019-08-30       Impact factor: 2.979

Review 7.  Measuring and modelling concurrency.

Authors:  Larry Sawers
Journal:  J Int AIDS Soc       Date:  2013-02-12       Impact factor: 5.396

8.  Helminthic infections rates and malaria in HIV-infected pregnant women on anti-retroviral therapy in Rwanda.

Authors:  Emil Ivan; Nigel J Crowther; Eugene Mutimura; Lawrence Obado Osuwat; Saskia Janssen; Martin P Grobusch
Journal:  PLoS Negl Trop Dis       Date:  2013-08-15

Review 9.  Malaria and HIV coinfection in sub-Saharan Africa: prevalence, impact, and treatment strategies.

Authors:  Tebit E Kwenti
Journal:  Res Rep Trop Med       Date:  2018-07-27

10.  Spatial overlaps in the distribution of HIV/AIDS and malaria in Zimbabwe.

Authors:  Isaiah Gwitira; Amon Murwira; Joseph Mberikunashe; Mhosisi Masocha
Journal:  BMC Infect Dis       Date:  2018-11-27       Impact factor: 3.090

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.